5.38Open5.38Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover640.25%IV-455.84%PremiumJan 17, 2025Expiry Date19.42Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6870Delta0.0751Gamma0.15Leverage Ratio-0.0374Theta-0.0081Rho-0.11Eff Leverage0.0027Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet